Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;24(8):1167-88.
doi: 10.1016/j.jvir.2013.04.023. Epub 2013 Jun 28.

Cancer concepts and principles: primer for the interventional oncologist-part II

Ryan Hickey  1 , Michael Vouche, Daniel Y Sze, Elias Hohlastos, Jeremy Collins, Todd Schirmang, Khairuddin Memon, Robert K Ryu, Kent Sato, Richard Chen, Ramona Gupta, Scott Resnick, James Carr, Howard B Chrisman, Albert A Nemcek Jr, Robert L Vogelzang, Robert J Lewandowski, Riad Salem
Affiliations
Review

Cancer concepts and principles: primer for the interventional oncologist-part II

Ryan Hickey et al. J Vasc Interv Radiol. 2013 Aug.

Abstract

This is the second of a two-part overview of the fundamentals of oncology for interventional radiologists. The first part focused on clinical trials, basic statistics, assessment of response, and overall concepts in oncology. This second part aims to review the methods of tumor characterization; principles of the oncology specialties, including medical, surgical, radiation, and interventional oncology; and current treatment paradigms for the most common cancers encountered in interventional oncology, along with the levels of evidence that guide these treatments.

Keywords: 5-FU; 5-fluorouracil; AFP; AJCC; American Joint Committee on Cancer; BCLC; Barcelona Clinic Liver Cancer; CRC; CapeOx; DEB; DEBIRI; EASL; EGFR; European Association for Study of the Liver; FOLFIRI; FOLFOX; HCC; IRE; NCCN; NCI; NET; NSCLC; National Cancer Institute; National Comprehensive Cancer Network; PV; RF; RT; VEGFR; capecitabine/oxaliplatin; colorectal cancer; drug-eluting bead; drug-eluting beads with irinotecan; epidermal growth factor receptor; hepatocellular carcinoma; irinotecan/5-fluorouracil/leucovorin; irreversible electroporation; neuroendocrine tumor; non–small-cell lung cancer; oxaliplatin/5-fluorouracil/leucovorin; portal vein; radiation therapy; radiofrequency; vascular endothelial growth factor receptor; α-fetoprotein.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Dan Sze reports the following disclosures: scientific advisory boards (Jenerex Biotherapeutics, SureFire Medical, Treus Medical, RadGuard Medical, Lunar Design); speaker’s bureau (WL Gore), consultant (BTG, Sirtex). Robert Lewandowski reports the following disclosures: scientific advisory board (Surefire, Nordion). Riad Salem reports the following disclosures: scientific advisory board and consultant (BMS, Abbott, Bayer/Onyx, NCCN, Merit, BTG, Nordion, Sirtex, Boston Scientific). None of the other authors report a conflict of interest.

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

References

    1. American Joint Committee on Cancer. Available from: http://www.cancerstaging.org/
    1. National Cancer Institute. Fact Sheet: Tumor Markers. Available from: < http://www.cancer.gov/cancertopics/factsheet/detection/tumor-markers>.
    1. National Cancer Institute Physician Data Query (PDQ) Available from: http://www.cancer.gov/cancertopics/pdq. - PubMed
    1. National Comprehensive Cancer Network (NCCN) Available from: http://www.nccn.org/
    1. National Cancer Institute Cancer Therapy Evaluation Program (CTEP) Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html.

Publication types